Eosinophil subtypes in asthmatic patients treated with mepolizumab, omalizumab and dupilumab

Introduction Two eosinophil subtypes, resident (rEos) and inflammatory (iEos), have been identified, first in mice and later in asthmatic patients. The effects of different biologics on these subpopulations remain unclear. This study evaluates the impact of mepolizumab, dupilumab and omalizumab on the proportion of rEos and iEos in asthmatic patients over 52 weeks. Methods We conducted a prospective study with 1-year follow-up of 82 patients with severe asthma: 28 were not receiving biologic therapy, 24 were treated with mepolizumab, 20 with dupilumab and 10 with omalizumab. Clinical variables included Asthma Control Test, exacerbation history and lung function. Blood samples underwent flow cytometry to classify eosinophils into (Siglec-8 + CD62L lo+ CD11b hi ) for iEos and (Siglec-8 + CD62L hi+ CD11b lo ) for rEos. Interleukin (IL)-5 receptor expression and levels of free IL-5 and eotaxin I/II were also assessed. Results Mepolizumab significantly reduced eosinophil concentrations compared with other groups (p